1.655

2.73% 0.045

Inovio Pharmaceuticals Inc (INO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Inovio Pharmaceuticals Inc stock is traded at $1.655, with a volume of 475.80K. It is up +2.73% in the last 24 hours and down -8.62% over the past month. Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Previous Close:

$1.61

Open:

$1.61

24h Volume:

475.80K

Relative Volume:

0.40

Market Cap:

$114.35M

Revenue:

$65,300

Net Income/Loss:

$-84.95M

P/E Ratio:

-0.8561

EPS:

-1.9332

Net Cash Flow:

$-88.92M

1W Performance:

+2.73%

1M Performance:

-8.62%

6M Performance:

-29.32%

1Y Performance:

-4.39%

1-Day Range:

$1.56

$1.675

1-Week Range:

$1.50

$1.675

52-Week Range:

$1.30

$2.9789

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name

Inovio Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (620)

Phone

(858) 410-3134

Address

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Employee

112

Twitter

@inoviopharma

Next Earnings Date

2026-03-12

Latest SEC Filings

INO's Discussions on Twitter

Compare INO vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INO Inovio Pharmaceuticals Inc	1.655	111.24M	65,300	-84.95M	-88.92M	-1.9332
VRTX Vertex Pharmaceuticals Inc	438.89	110.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	752.45	77.99B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	703.12	42.91B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.13	42.09B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	152.83	31.32B	606.42M	-1.28B	-997.58M	-6.403

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-09-25	Initiated	Piper Sandler	Overweight
May-14-24	Initiated	Stephens	Overweight
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral
Dec-29-21	Resumed	Jefferies	Hold
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-24-21	Initiated	Jefferies	Hold
Mar-23-21	Initiated	BofA Securities	Neutral
Feb-12-21	Initiated	Oppenheimer	Outperform
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-28-20	Upgrade	Maxim Group	Hold → Buy
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold
May-21-20	Initiated	The Benchmark Company	Buy
Apr-30-20	Downgrade	ROTH Capital	Buy → Neutral
Mar-13-20	Downgrade	Piper Sandler	Overweight → Neutral
Mar-13-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-19-19	Initiated	ROTH Capital	Buy
Feb-15-18	Reiterated	Maxim Group	Buy
Oct-18-17	Initiated	RBC Capital Mkts	Outperform
Sep-06-17	Initiated	Citigroup	Buy
Jun-08-17	Upgrade	Piper Jaffray	Neutral → Overweight
May-24-17	Reiterated	Maxim Group	Buy
Mar-16-17	Upgrade	Maxim Group	Hold → Buy
Mar-16-17	Downgrade	Piper Jaffray	Overweight → Neutral

View All

Inovio Pharmaceuticals Inc Stock (INO) Latest News

03:46 AM

INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - prnewswire.com

03:46 AM

Mar 29, 2026

INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026 - prnewswire.com

Mar 29, 2026

Mar 28, 2026

Aug Fed Impact: Whats the MACD signal for Inovio Pharmaceuticals Inc2026 PreEarnings & Weekly Return Optimization Plans - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

INO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Inovio Pharmaceuticals Inc. Investors ... - Bluefield Daily Telegraph

Mar 27, 2026

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 27, 2026

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - The Globe and Mail

Mar 27, 2026

Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire

Mar 27, 2026

INO Shareholder Alert: Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph

Mar 27, 2026

INO Shareholder Alert: Inovio Pharmaceuticals, Inc. - GlobeNewswire

Mar 27, 2026

INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - chartmill.com

Mar 27, 2026

Mar 26, 2026

SRPT Stock Surges on Promising Early Results From siRNA Programs - The Globe and Mail

Mar 26, 2026

BEAM Eyes Global Expansion of AATD Study After Strong Early Data - The Globe and Mail

Mar 26, 2026

Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire

Mar 26, 2026

Market Overview: How correlated is Inovio Pharmaceuticals Inc to the S P5002026 Update & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Mar 26, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain OfficersINO - PR Newswire

Mar 26, 2026

Inovio Q4 2025 slides: BLA accepted but FDA questions linger By Investing.com - Investing.com Canada

Mar 26, 2026

Inovio Q4 2025 slides: BLA accepted but FDA questions linger - Investing.com

Mar 26, 2026

Earnings call transcript: Inovio Q4 2025 earnings miss, stock dips - Investing.com

Mar 26, 2026

Mar 25, 2026

Bragar Eagel & Squire, P.C. Reminds Investors that a Class - GlobeNewswire

Mar 25, 2026

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mar 25, 2026